"We are thrilled to bring premium resin cartridges to the Australian market, a signal of our commitment to expanding patient access to an even greater variety of premium cannabis," said Kristin Viccars, Interim Managing Director, MedReleaf Australia. "Our products are designed with the highest standards of quality with safety in mind, and we are confident that Australian patients will value the unique experience our cartridges offer. We continue to look at new opportunities to expand our portfolio and patie ...

Short-squeeze moves can be ferocious and are perfect for investors seeking quick trading gains. With the possibility of a rate cut-induced rally, I am bullish on some short-squeeze stocks for the next few quarters.I am a long-term investor. However, I don’t shy away from taking trading positions in 5% to 10% of my fund allocation towards equities. When there are some clear short-squeeze opportunities, it makes sense to make 50% or 100% gains and invest the profits in long term bets. Of course, the short-squ ...

Group 1: Meme Stock Euphoria - The current market sentiment indicates that meme stock euphoria is in its early stages, with potential rate cuts likely to boost economic growth and trigger a full-fledged meme stock season [1] - A 50% rally in short-squeeze stocks is expected, with the possibility of a 2x or 3x rally in a few months if the meme stock euphoria gains momentum [1] Group 2: Lucid Group (LCID) - Lucid Group's stock has seen a significant downturn, with a correction of nearly 60% over the past year, but it is considered a candidate for a short-squeeze rally [3] - The announcement of a 100% tariff on Chinese-made electric vehicles by Biden could serve as a catalyst for a rally from oversold levels [3] - Lucid has a liquidity buffer of $5 billion, and the management is optimistic about the upcoming launch of Lucid Gravity, which may attract speculative interest [3] Group 3: Aurora Cannabis (ACB) - Aurora Cannabis is identified as having high short interest and is positioned for a potential rally, especially with the upcoming presidential elections where cannabis legalization will be a key topic [5][6] - The company's international medicinal cannabis revenue increased by 41% year-on-year for Q3 2024, indicating healthy revenue growth that could lead to EBITDA margin expansion [6] Group 4: Beyond Meat (BYND) - Beyond Meat's stock has experienced a significant decline, trading in single digits after being near $200 at the end of 2022, yet it remains oversold with short interest above 40% [7] - The company reported a revenue decline of 18% year-on-year to $75.6 million for Q1 2024, along with an adjusted EBITDA loss of $32.9 million, indicating struggles [7] - The launch of the fourth generation of Beyond Burger and Beyond Beef may positively impact financials, and the current oversold levels could trigger a short-squeeze rally [8]

Core Viewpoint - Aurora Cannabis has seen significant stock performance in 2024, with over 40% gains, driven by potential U.S. marijuana market reforms, particularly the Biden Administration's move to reclassify marijuana to Schedule III from Schedule I [1][2]. Group 1: Market Developments - The Biden Administration's plans to reschedule cannabis have generated excitement in the pot stock market, with Aurora's stock surging 46% on the announcement day [2]. - Rescheduling cannabis indicates a recognition of its potential medical uses, which could pave the way for medicinal marijuana acceptance in the U.S. [2][3]. Group 2: Company Positioning - Aurora has been pivoting towards the medical marijuana sector, which typically offers higher margins, positioning itself favorably if further reforms occur [3]. - The company is streamlining operations to become more efficient, focusing on the medicinal market, which may be legalized before recreational use [3]. Group 3: Financial Performance - In the last quarter of 2023, Aurora reported a net loss of 25.6 million Canadian dollars, despite showing a profit on an adjusted EBITDA basis [4]. - The company's net revenue was CA$64.4 million, reflecting a 5% growth, but this was against a weak comparable, highlighting ongoing challenges in consistent growth [5]. Group 4: Investment Considerations - While Aurora may attract contrarian investors due to potential U.S. marijuana reform, the sustainability of its operations remains in question [4][5]. - The stock has lost over 90% of its value in the past three years, indicating significant volatility and risk for investors [7].

Among the emerging industries that have captured the attention of investors is the cannabis sector. The cannabis industry has experienced remarkable growth, giving rise to a new breed of top cannabis stocks to buy for investments in May.Although the results so far from the cannabis industry have disappointed many investors, I feel that the long-term prospects remain promising. While the initial hype and optimism surrounding the legalization of cannabis may have led to unrealistic expectations, it is importa ...

NASDAQ | TSX: ACBCanada's Leading Medical Cannabis Company Launches Premium Products Redefining Patient CareEDMONTON, AB, May 8, 2024 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) the Canadian based leading global medical cannabis company, is proud to announce the arrival of Aurora branded medical cannabis products to the New Zealand market. This new line of premium dried flowers represents a significant milestone in medical cannabis accessibility in New Zealand, an emerging market poised for ...

Aurora Cannabis Inc. (ACB) shares soared 46% in the last trading session to close at $9.23. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 46.6% gain over the past four weeks.The sharp upsurge in Aurora's shares can be attributed to the DEA's reported decision to reclassify marijuana from Schedule I (reserved for drugs with a high potential for abuse) to Schedule III (reserved for drugs with a moderate to low potential for physi ...

The US is planning to reclassify cannabis as a less dangerous drug in an historic shift that could have a significant impact across the country.The Drug Enforcement Administration's (DEA) proposal would recognise the drug's medical properties and acknowledge it has less potential for abuse than other dangerous substances. However the proposal, which still must be reviewed by the White House, would not legalise cannabis outright for recreational use.Marijuana is currently classified in the US as a "schedule ...

Cannabis stocks soared nearly across the board this afternoon on news that President Joe Biden’s administration is moving to reschedule marijuana as a Schedule III substance, a less severe designation than its prior Schedule I classification. Indeed, acting on a review from the Department of Health and Human Substances, the U.S. Drug Enforcement Administration (DEA) and U.S. Justice Department may recategorize cannabis as early as this week. A move to Schedule III would yield major benefits to both the lega ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...